triumph 1 retatrutide Reduces Body Weight by Nearly 30% in Phase 3 TRIUMPH-1 Trial, With Gains for Sleep Apnea and Knee Pain triumph-1 retatrutide As an obesity

Explore dosage ranges, common side effects, and safety considerations before starting treatment.

The GLP-1 Breakthrough: A Cardiologists Secrets to Lasting Weight Loss and a Healthier Heart

Women in the study who were obese and taking GLP-1 weight loss medications were 30% less likely to develop breast cancer than other women.

- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Amylyx endocrine and neuroscience expertise and aligns with pipeline focus of delivering important potential treatment options to communities with high unmet needs - Phase 3 program for avexitide in PBH expected to begin in Q1 2025, with data readout anticipated in 2026

Reality check: this is still preclinical

Chrissy Teigen opened up about the importance of transparency and why she revealed she'd taken Ozempic to help her lose weight after her miscarriage.